Results 71 to 80 of about 16,087 (221)
Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway
BiomoleculesRecently, the vascular protective effect of anti-diabetic agents has been receiving much attention. Sodium glucose cotransporter 2 (SGLT2) inhibitors had demonstrated reductions in cardiovascular (CV) events.
Li Han +9 more
doaj +1 more source
Smart Molecules, EarlyView.A green and simple photo‐oxygenation of benzylic C‐H bond with molecular oxygen was developed for the preparation of a series of carbonyl compounds. The straightforward C‐H carbonylation strategy features catalyst‐ and additive‐free reaction conditions, only oxygen as a green oxidant, broad scope and scalable, and the simple‐operation nature.
Jianing Li +6 more
wiley +1 more source
Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
VIEW, EarlyView.This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley +1 more source
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale +5 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller +12 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons +11 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert +12 more
wiley +1 more source